Skip to main content
. Author manuscript; available in PMC: 2014 Sep 15.
Published in final edited form as: Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004185. doi: 10.1002/14651858.CD004185.pub2
Methods Six-week randomised, double-blind study.
Participants Outpatients fulfilling DSM-III criteria for major depression, with a score between 18 and 25 on the HDRS-21.
Age range: 18-65 years old.
Exclusion criteria: organic brain disease, seizures, other serious illness, hyperthyrodism, allergy, drug or alcohol abuse, use of MAOI within 2 week, serious suicidal risk, pregancy and lactation
Interventions Fluoxetine: 31 participants.
Amineptine: 32 participants.
Fluoxetine dose: 20 mg/day.
Amineptine dose: 200 mg/day.
Outcomes Hamilton Rating Scale for Depression (HDRS-21), Montgomery and Asberg Scale for Depression (MADRS), CGI for Severity
Notes Funding: unclear
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear